KRAS and non-small cell lung carcinoma: The study also demonstrated that combined treatment with the SOS1 inhibitor BI-3406 plus the MEK inhibitor trametinib effectively reduced the viability of KRAS G12C-mutant NSCLC cells, in which the Y96D or Y96S mutant was exogenously introduced.